Pharmaceutical Practice in One AASV Patient with Pulmonary Fibrosis Treated with Cyclophosphamide
- VernacularTitle:1例环磷酰胺用于合并肺间质纤维化的AASV患者的药学实践
- Author:
Donghong YIN
;
Junli SONG
;
Jinju DUAN
;
Zhihong REN
- Keywords:
Clinical pharmacists;
Cyclophosphamide;
Pulmonary fibrosis;
Antineutrophil cytoplasmic antibody associated with systemic vasculitis
- From:
China Pharmacist
2017;20(2):295-297
- CountryChina
- Language:Chinese
-
Abstract:
It is recommended that cyclophosphamide combined with corticosteroids should be used as the first-line treatment of ANCA ( antineutrophil cytoplasmic antibody) associated with systemic vasculitis ( AASV) , however, cyclophosphamide has notable ad-verse reaction of causing pulmonary fibrosis ( PF) . In this paper, whether cyclophosphamide should be used in an AASF patient with PF was analyzed in order to decide whether AASV with PF is one of contraindications of cyclophosphamide in clinical practice.
